Targeted Inhibition of Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibits Proliferation and Induces Apoptosis of Laryngeal Carcinoma Cells in vitro

Sun G. , Wang Y. , Zhu Y. , Huang C. , Ji Q. : Duffy antigen receptor for chemokines in laryngeal squamous cell carcinoma as a negative regulator. Acta Otolaryngol, 131: 197–203, 2011.

Mnejja M. , Hammami B. , Bougacha L. , Chakroun A. , Charfeddine I. , Khabir A. , Boudaoura T. , Ghorbel A. : Occult lymph node metastasis in laryngeal squamous cell carcinoma: therapeutic and prognostic impact. Eur Ann Otorhinolaryngol Head Neck Dis, 127: 173–176, 2010.

Amar A. , Chedid H.M. , Franzi S.A. , Rapoport A. : Diagnostic and therapeutic delay in patients with larynx cancer at a reference public hospital. Braz J Otorhinolaryngol, 76: 700–703, 2010.

Baujat B. , Bourhis J. , Blanchard P. , Overgaard J. , Ang K.K. , Saunders M. , Le Maître A. , Bernier J. , Horiot J.C. , Maillard E. , Pajak T.F. , Poulsen M.G. , Bourredjem A. , O'Sullivan B. , Dobrowsky W. , Andrzej H. , Skladowski K. , Hay J.H. , Pinto L.H. , Fu K.K. , Fallai C. , Sylvester R. , Pignon J.P. : MARCH Collaborative Group: Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev, CD002026, 2010.

Milisavljevic D. , Stankovic M. , Zivic M. , Popovic M. , Radovanovi Z. : Factors affecting results of treatment of hypopharyngeal carcinoma. Hippokratia, 13: 154–160, 2009.

Reizenstein J.A. , Bergström S.N. , Holmberg L. , Linder A. , Ekman S. , Blomquist E. , Lödén B. , Holmqvist M. , Hellström K. , Nilsson C.O. , Brattström D. , Bergqvist M. : Impact of age at diagnosis on prognosis and treatment in laryngeal cancer. Head Neck, 32: 1062–1068, 2010.

Semrau S. , Waldfahrer F. , Lell M. , Linke R. , Klautke G. , Kuwert T. , Uder M. , Iro H. , Fietkau R. : Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradiotherapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol, 187: 15–22, 2011.

Prince A. , Aguirre-Ghizo J. , Genden E. , Posner M. , Sikora A. : Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med, 77: 684–699, 2010.

Zhang H. , Zhang D. , Luan X. , Xie G. , Pan X. : Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res, 38: 1673–1681, 2010.

Liu Y.Y. , Sun L.C. , Wei J.J. , Li D. , Yuan Y. , Yan B. , Liang Z.H. , Zhu H.F. , Xu Y. , Li B. , Song C.W. , Liao S.J. , Lei Z. , Zhang G.M. , Feng Z.H. : Tumor Cell-released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol, 185: 2773–2782, 2010.

Filipowicz W. , Grosshans H. : The liver-specific microRNA miR-122: biology and therapeutic potential. Prog Drug Res, 67: 221–238, 2011.

Yanfeng Wu , Xinjun Liang , Yanyan Liu , Gong W. , Liu J.X. , Wang X.P. , Zhuang Z.Q. , Guo Y. , Shen H.Y. : Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma, 57: 501–506, 2010.

Tian L. , Chen X. , Sun Y. , Liu M. , Zhu D. , Ren J. : Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12. J Int Med Res, 38: 994–1004, 2010.

Liu J. , Tan L. , Li H. , Wang Q. , Ji W. : Suppression of S-phase kinase-associated protein 2 induces apoptosis and inhibits tumor growth in human laryngeal cancer. ORL J Otorhinolaryngol Relat Spec, 72: 205–214, 2010.

Hata K. , Watanabe Y. , Nakai H. , Hata T. , Hoshiai H. : Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy. Anticancer Res, 31: 731–737, 2011.

Liang X. , Da M. , Zhuang Z. , Wu W. , Wu Z. , Wu Y. , Shen H. : Effects of survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int, 33: 119–124, 2009.

De Martino M.C. , van Koetsveld P.M. , Hofland L.J. : Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology, 92 (Suppl 1): 28–34, 2010.

Martelli A.M. , Evangelisti C. , Chiarini F. , Grimaldi C. , Cappellini A. , Ognibene A. , McCubrey J.A. : The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta, 1803: 991–1002, 2010.

Dello Russo C. , Lisi L. , Tringali G. , Navarra P. : Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol, 78: 1242–1251, 2009.

Singh G. , Akcakanat A. , Sharma C. , Luyimbazi D. , Naff K.A. , Meric-Bernstam F. : The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer, 63: 264–271, 2011.

Memmott R.M. , Dennis P.A. : The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res, 16: 4–10, 2010.

Hashimoto I. , Koizumi K. , Tatematsu M. , Minami T. , Cho S. , Takeno N. , Nakashima A. , Sakurai H. , Saito S. , Tsukada K. , Saiki I. : Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer, 44: 1022–1029, 2008.

Scott K.L. , Kabbarah O. , Liang M.C. , Ivanova E. , Anagnostou V. , Wu J. , Dhakal S. , Wu M. , Chen S. , Feinberg T. , Huang J. , Saci A. , Widlund H.R. , Fisher D.E. , Xiao Y. , Rimm D.L. , Protopopov A. , Wong K.K. , Chin L. : GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 459: 1085–1090, 2009.

Sircar K. , Yoshimoto M. , Monzon F.A. , Koumakpayi I.H. , Katz R.L. , Khanna A. , Alvarez K. , Chen G. , Darnel A.D. , Aprikian A.G. , Saad F. , Bismar T.A. , Squire J.A. : PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol, 218: 505–513, 2009.

Rai J.S. , Henley M.J. , Ratan H.L. : Mammalian target of rapamycin: a new target in prostate cancer. Urol Oncol, 28: 134–138, 2010.

Guo Y. , Liang X. , Lu M. , Weng T. , Liu Y. , Ye X. : Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma. Hepatogastroenterology, 57: 913–918, 2010.

Ji C. , Yang B. , Yang Y.L. , He S.H. , Miao D.S. , He L. , Bi Z.G. : Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene, 29: 6557–6568, 2010.

Sliva K. , Schnierle B.S. : Selective gene silencing by viral delivery of short hairpin RNA. Virol J, 7: 248, 2010.

Lee W.T. , Tubbs R.R. , Teker A.M. , Scharpf J. , Strome M. , Wood B. , Lorenz R.R. , Hunt J. : Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. Arch Pathol Lab Med, 132: 1653–1656, 2008.

García-Martínez J.M. , Wullschleger S. , Preston G. , Guichard S. , Fleming S. , Alessi D.R. , Duce S.L. : Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer, 104: 1116–1125, 2011.

Clegg N.J. , Couto S.S. , Wongvipat J. , Hieronymus H. , Carver B.S. , Taylor B.S. , Ellwood-Yen K. , Gerald W.L. , Sander C. , Sawyers C.L. : MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One, 6: e17449, 2011.

Zhou H. , Huang S. : Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci, 12: 30–42, 2011.

Liu J. , Stevens P.D. , Gao T. : mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem, 286: 6510–6520, 2011.

Noske A. , Lindenberg J.L. , Darb-Esfahani S. , Weichert W. , Buckendahl A.C. , Röske A. , Sehouli J. , Dietel M. , Denkert C. : Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep, 20: 1409–1417, 2008.

Kim E.K. , Kim H.A. , Koh J.S. , Kim M.S. , Kim K.I. , Lee J.I. , Moon N.M. , Ko E. , Noh W.C. : Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat, 126: 93–99, 2011.

Mori K. , Blanchard F. , Charrier C. , Battaglia S. , Ando K. , Duplomb L. , Shultz L.D. , Redini F. , Heymann D. : Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Sci, 99: 2170–2176, 2008.

Matsumoto K. , Arao T. , Tanaka K. , Kaneda H. , Kudo K. , Fujita Y. , Tamura D. , Aomatsu K. , Tamura T. , Yamada Y. , Saijo N. , Nishio K. : mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res, 69: 7160–7164, 2009.

Garcia-Echeverria C. : Blocking the mTOR pathway: a drug discovery perspective. Biochem Soc Trans, 39: 451–455, 2011.

Ghayad S.E. , Bieche I. , Vendrell J.A. , Keime C. , Lidereau R. , Dumontet C. , Cohen P.A. : mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci, 99: 1992–2003, 2008.

Dasanu C.A. , Clark BA 3rd , Alexandrescu D.T. : mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opin Investig Drugs, 18: 175–187, 2009.